Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies

Douglas A. Collins, Harry P C Hogenkamp, Michael K. O'Connor, Stephen Naylor, Linda M. Benson, Timothy J. Hardyman, Linda M. Thorson

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Objective: To study the biodistribution of a vitamin B12 analog, indium In 111-labeled diethylenetriaminepentaacetate adenosylcobalamin (In 111 DAC), in patients recently diagnosed as having primary or recurrent malignancy. Patients and Methods: Thirty patients (14 women and 16 men) with radiographically or clinically diagnosed breast, lung, colon, sarcomatous, thyroid, or central nerVous system malignancies were studied prior to definitive surgery or biopsy. A maximum of 650 μCi (2.2 μg) of In 111 DAC was administered intravenously. Vitamin B12 and folate levels were determined prior to injection. Serum clearance and urinary and stool excretion of the tracer were measured. Images were routinely obtained at 0.5, 3 to 5, and 20 to 24 hours after injection. Biodistribution of In 111 DAC was determined by computer analysis of regions of interest. Results: Serum T(1/2) clearance was 7 minutes. Average urinary and stool excretion of the injected dose over 24 hours was 26.1% and 0.4%, respectively. The greatest focal uptake of In 111 DAC occurred in the liver and spleen, followed by the nasal cavity and salivary and lacrimal glands. The average tumor uptake of the injected dose was 2% at 30 minutes and 1.5% at 24 hours. High-grade primary and metastatic breast, lung; colon, thyroid, and sarcomatous malignancies were all imaged at 3 to 5 hours after injection. Central nervous system tumors and advanced metastatic prostate cancer were best identified at 24 hours. Mammographically occult, palpable, and nonpalpable breast cancers were delineated by In 111 DAC. Low-grade malignancies as well as early skeletal metastatic disease were not effectively imaged by the vitamin B12 tracer. Patients with elevated baseline vitamin B12 or those concurrently taking corticosteroids appeared to have optimal visualization of their malignancies. Conclusion: Vitamin B12 may be a useful vehicle for delivering diagnostic and therapeutic agents to various malignancies. Further evaluation of cobalamin analogs and their interaction with transport proteins and cellular receptors within malignant tissue and infection is warranted.

Original languageEnglish (US)
Pages (from-to)568-580
Number of pages13
JournalMayo Clinic Proceedings
Volume75
Issue number6
StatePublished - 2000

Fingerprint

Vitamin B 12
Indium
Neoplasms
Injections
Thyroid Gland
Colon
Breast
Central Nervous System Neoplasms
Lacrimal Apparatus
Lung
Nasal Cavity
cobamamide
Salivary Glands
Serum
Folic Acid
Prostatic Neoplasms
Carrier Proteins
Adrenal Cortex Hormones
Spleen
Central Nervous System

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Collins, D. A., Hogenkamp, H. P. C., O'Connor, M. K., Naylor, S., Benson, L. M., Hardyman, T. J., & Thorson, L. M. (2000). Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. Mayo Clinic Proceedings, 75(6), 568-580.

Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. / Collins, Douglas A.; Hogenkamp, Harry P C; O'Connor, Michael K.; Naylor, Stephen; Benson, Linda M.; Hardyman, Timothy J.; Thorson, Linda M.

In: Mayo Clinic Proceedings, Vol. 75, No. 6, 2000, p. 568-580.

Research output: Contribution to journalArticle

Collins, DA, Hogenkamp, HPC, O'Connor, MK, Naylor, S, Benson, LM, Hardyman, TJ & Thorson, LM 2000, 'Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies', Mayo Clinic Proceedings, vol. 75, no. 6, pp. 568-580.
Collins DA, Hogenkamp HPC, O'Connor MK, Naylor S, Benson LM, Hardyman TJ et al. Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. Mayo Clinic Proceedings. 2000;75(6):568-580.
Collins, Douglas A. ; Hogenkamp, Harry P C ; O'Connor, Michael K. ; Naylor, Stephen ; Benson, Linda M. ; Hardyman, Timothy J. ; Thorson, Linda M. / Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. In: Mayo Clinic Proceedings. 2000 ; Vol. 75, No. 6. pp. 568-580.
@article{77e4787c0e6f4c50ab6dc4242cce59ee,
title = "Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies",
abstract = "Objective: To study the biodistribution of a vitamin B12 analog, indium In 111-labeled diethylenetriaminepentaacetate adenosylcobalamin (In 111 DAC), in patients recently diagnosed as having primary or recurrent malignancy. Patients and Methods: Thirty patients (14 women and 16 men) with radiographically or clinically diagnosed breast, lung, colon, sarcomatous, thyroid, or central nerVous system malignancies were studied prior to definitive surgery or biopsy. A maximum of 650 μCi (2.2 μg) of In 111 DAC was administered intravenously. Vitamin B12 and folate levels were determined prior to injection. Serum clearance and urinary and stool excretion of the tracer were measured. Images were routinely obtained at 0.5, 3 to 5, and 20 to 24 hours after injection. Biodistribution of In 111 DAC was determined by computer analysis of regions of interest. Results: Serum T(1/2) clearance was 7 minutes. Average urinary and stool excretion of the injected dose over 24 hours was 26.1{\%} and 0.4{\%}, respectively. The greatest focal uptake of In 111 DAC occurred in the liver and spleen, followed by the nasal cavity and salivary and lacrimal glands. The average tumor uptake of the injected dose was 2{\%} at 30 minutes and 1.5{\%} at 24 hours. High-grade primary and metastatic breast, lung; colon, thyroid, and sarcomatous malignancies were all imaged at 3 to 5 hours after injection. Central nervous system tumors and advanced metastatic prostate cancer were best identified at 24 hours. Mammographically occult, palpable, and nonpalpable breast cancers were delineated by In 111 DAC. Low-grade malignancies as well as early skeletal metastatic disease were not effectively imaged by the vitamin B12 tracer. Patients with elevated baseline vitamin B12 or those concurrently taking corticosteroids appeared to have optimal visualization of their malignancies. Conclusion: Vitamin B12 may be a useful vehicle for delivering diagnostic and therapeutic agents to various malignancies. Further evaluation of cobalamin analogs and their interaction with transport proteins and cellular receptors within malignant tissue and infection is warranted.",
author = "Collins, {Douglas A.} and Hogenkamp, {Harry P C} and O'Connor, {Michael K.} and Stephen Naylor and Benson, {Linda M.} and Hardyman, {Timothy J.} and Thorson, {Linda M.}",
year = "2000",
language = "English (US)",
volume = "75",
pages = "568--580",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies

AU - Collins, Douglas A.

AU - Hogenkamp, Harry P C

AU - O'Connor, Michael K.

AU - Naylor, Stephen

AU - Benson, Linda M.

AU - Hardyman, Timothy J.

AU - Thorson, Linda M.

PY - 2000

Y1 - 2000

N2 - Objective: To study the biodistribution of a vitamin B12 analog, indium In 111-labeled diethylenetriaminepentaacetate adenosylcobalamin (In 111 DAC), in patients recently diagnosed as having primary or recurrent malignancy. Patients and Methods: Thirty patients (14 women and 16 men) with radiographically or clinically diagnosed breast, lung, colon, sarcomatous, thyroid, or central nerVous system malignancies were studied prior to definitive surgery or biopsy. A maximum of 650 μCi (2.2 μg) of In 111 DAC was administered intravenously. Vitamin B12 and folate levels were determined prior to injection. Serum clearance and urinary and stool excretion of the tracer were measured. Images were routinely obtained at 0.5, 3 to 5, and 20 to 24 hours after injection. Biodistribution of In 111 DAC was determined by computer analysis of regions of interest. Results: Serum T(1/2) clearance was 7 minutes. Average urinary and stool excretion of the injected dose over 24 hours was 26.1% and 0.4%, respectively. The greatest focal uptake of In 111 DAC occurred in the liver and spleen, followed by the nasal cavity and salivary and lacrimal glands. The average tumor uptake of the injected dose was 2% at 30 minutes and 1.5% at 24 hours. High-grade primary and metastatic breast, lung; colon, thyroid, and sarcomatous malignancies were all imaged at 3 to 5 hours after injection. Central nervous system tumors and advanced metastatic prostate cancer were best identified at 24 hours. Mammographically occult, palpable, and nonpalpable breast cancers were delineated by In 111 DAC. Low-grade malignancies as well as early skeletal metastatic disease were not effectively imaged by the vitamin B12 tracer. Patients with elevated baseline vitamin B12 or those concurrently taking corticosteroids appeared to have optimal visualization of their malignancies. Conclusion: Vitamin B12 may be a useful vehicle for delivering diagnostic and therapeutic agents to various malignancies. Further evaluation of cobalamin analogs and their interaction with transport proteins and cellular receptors within malignant tissue and infection is warranted.

AB - Objective: To study the biodistribution of a vitamin B12 analog, indium In 111-labeled diethylenetriaminepentaacetate adenosylcobalamin (In 111 DAC), in patients recently diagnosed as having primary or recurrent malignancy. Patients and Methods: Thirty patients (14 women and 16 men) with radiographically or clinically diagnosed breast, lung, colon, sarcomatous, thyroid, or central nerVous system malignancies were studied prior to definitive surgery or biopsy. A maximum of 650 μCi (2.2 μg) of In 111 DAC was administered intravenously. Vitamin B12 and folate levels were determined prior to injection. Serum clearance and urinary and stool excretion of the tracer were measured. Images were routinely obtained at 0.5, 3 to 5, and 20 to 24 hours after injection. Biodistribution of In 111 DAC was determined by computer analysis of regions of interest. Results: Serum T(1/2) clearance was 7 minutes. Average urinary and stool excretion of the injected dose over 24 hours was 26.1% and 0.4%, respectively. The greatest focal uptake of In 111 DAC occurred in the liver and spleen, followed by the nasal cavity and salivary and lacrimal glands. The average tumor uptake of the injected dose was 2% at 30 minutes and 1.5% at 24 hours. High-grade primary and metastatic breast, lung; colon, thyroid, and sarcomatous malignancies were all imaged at 3 to 5 hours after injection. Central nervous system tumors and advanced metastatic prostate cancer were best identified at 24 hours. Mammographically occult, palpable, and nonpalpable breast cancers were delineated by In 111 DAC. Low-grade malignancies as well as early skeletal metastatic disease were not effectively imaged by the vitamin B12 tracer. Patients with elevated baseline vitamin B12 or those concurrently taking corticosteroids appeared to have optimal visualization of their malignancies. Conclusion: Vitamin B12 may be a useful vehicle for delivering diagnostic and therapeutic agents to various malignancies. Further evaluation of cobalamin analogs and their interaction with transport proteins and cellular receptors within malignant tissue and infection is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0034082251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034082251&partnerID=8YFLogxK

M3 - Article

C2 - 10852417

AN - SCOPUS:0034082251

VL - 75

SP - 568

EP - 580

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -